| Literature DB >> 31755348 |
Wei Guan1,2, Yu Jing1, Liping Dou1, Maoquan Wang1,3, Yang Xiao1, Li Yu1,2,3.
Abstract
Chidamide, a novel histone deacetylase inhibitor, has exerted effects in T-cell tumors through various mechanisms. Seventeen patients with refractory or relapsed T-cell acute lymphoblastic lymphoma/leukemia (T-LBL/ALL) received Chidamide combined with chemotherapy as salvage treatment. Historical data was analyzed as comparison as chemotherapy group. Complete response (CR) rate and overall response rate (ORR) of Chidamide + chemotherapy group were higher than that of chemotherapy group after one course. Chidamide + chemotherapy group had a better progress-free survival (PFS) compared to chemotherapy group. No difference in overall survival (OS) was observed. Grade 3/4 nonhematological adverse events (>10%) of patients in Chidamide + chemotherapy group included febrile neutropenia (64.7%), drug-induced liver failure (17.6%), decreased fibrinogen (11.8%), sepsis (11.8%), pneumonitis (11.8%), and oral mucositis (11.8%). This study demonstrates that Chidamide included regimen may be a new treatment strategy with an acceptable safety profile for refractory or relapsed T-LBL/ALL patients but requires further investigation.Entities:
Keywords: Chidamide; Precursor T-cell lymphoblastic leukemia-lymphoma; early T-cell precursor acute lymphoblastic lymphoma/leukemia; hematopoietic stem cell transplantation; salvage therapy
Mesh：
Substances：
Year: 2019 PMID： 31755348 DOI： 10.1080/10428194.2019.1691195
Source DB: PubMed Journal: Leuk Lymphoma ISSN： 1026-8022